STOCK TITAN

Co-Diagnostics Inc - CODX STOCK NEWS

Welcome to our dedicated news page for Co-Diagnostics (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Co-Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Co-Diagnostics's position in the market.

Rhea-AI Summary
Co-Diagnostics, Inc. announces its list of events for November 2023, where it will showcase its Co-Dx™ PCR platform technology. The events include the Utah Life Sciences Summit and the AMP annual meeting in Salt Lake City.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
-
Rhea-AI Summary
Co-Diagnostics, Inc. (NASDAQ: CODX) will release its Q3 2023 results on November 9, 2023, after the market close. The company will host a conference call and webcast to discuss its financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
earnings
-
Rhea-AI Summary
Co-Diagnostics, Inc. announces participation in the Caribbean Association of Medical Technologies Scientific Symposium and BGM
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
conferences
Rhea-AI Summary
Co-Diagnostics to showcase at Africa Health/Medlab Africa conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
conferences
-
Rhea-AI Summary
Co-Diagnostics, Inc. sponsors Utah Health Care Association/Utah Center for Assisted Living Convention and introduces Co-Dx PCR Home platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
conferences
-
Rhea-AI Summary
Co-Diagnostics, Inc. to present at ACTC conference and share research on Co-Primers™ technology in liquid biopsy applications. Also, brief presentation on upcoming Co-Dx PCR Home™ platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Co-Diagnostics to present at Gilmartin Group Annual Emerging Growth Showcase, discussing progress on Co-Dx PCR Home platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences acquisition
-
Rhea-AI Summary
Co-Diagnostics, Inc. will be presenting at the H.C. Wainwright & Co. 25th Annual Global Investment Conference to discuss the progress on its forthcoming Co-Dx PCR Home platform. The presentation will be held on September 12, 2023, at 2:30 PM Eastern Time. The platform is subject to FDA review and is not available for sale.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
conferences
-
Rhea-AI Summary
Co-Diagnostics, Inc. sponsors and presents at Next Generation Dx Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
conferences
Rhea-AI Summary
Co-Diagnostics, Inc. will be hosting a booth at Asia Health/Medlab Asia 2023 in Bangkok, Thailand. The conference is a valuable platform for the healthcare industry, expecting over 7,500 attendees. The Company will showcase its Co-Primer™ PCR technology, infectious disease products, and upcoming Co-Dx PCR Home testing platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
conferences
Co-Diagnostics Inc

Nasdaq:CODX

CODX Rankings

CODX Stock Data

34.70M
30.41M
2.68%
15.79%
1.12%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Salt Lake City

About CODX

co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are